Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2019, Vol. 46 Issue (1): 66-71    DOI: 10.12891/ceog4358.2019
Original Research Previous articles | Next articles
Hormone therapy is not associated to pain thresholds in healthy postmenopausal women
O.B. Poli-Neto1, *(), P.S. Silva1, T. Mangetti Gonçalvez1, M.M. Máximo1, J.C. Rosa-e-Silva1, F.J. Candido-dos-Reis1, A.A. Nogueira1
1 Department of Gynecology and Obstetrics; Ribeirão Preto Medical School, University of São Paulo; Ribeirão Preto, São Paulo, Brazil
Download:  PDF(274KB)  ( 184 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose of Investigation: To evaluate if hormone replacement therapy modifies pain thresholds in healthy postmenopausal women. Study Design: A cross-sectional study including 78 healthy postmenopausal women. Materials and Methods: Pain thresholds were determined using pressure algometry and electrical stimulation. Participant interviews were followed by the application of a semistructured questionnaire including psychometric assessment with Beck Depression Inventory and State-Trait Anxiety Inventory. A 10-mL peripheral blood sample was collected after the interview. Serum concentrations of estradiol, progesterone, and testosterone were determined by chemoluminescence. Results: Users of the medication presented significantly lower sensory electrical thresholds (3.60 ± 0.85) than non-users (4.58 ± 1.30). No significant difference in pain threshold was observed between groups. Weak positive correlation between estradiol levels and sensory thresholds was observed (r = 0.26, p = 0.04). Conclusion: Hormone replacement therapy is not associated with modifications in pain thresholds, neither mechanical nor electrical ones, in healthy postmenopausal women.
Key words:  Hormone therapy      Postmenopausal women      Pain threshold     
Published:  10 February 2019     
*Corresponding Author(s):  O.B. POLI-NETO     E-mail:  polineto@fmrp.usp.br

Cite this article: 

O.B. Poli-Neto, P.S. Silva, T. Mangetti Gonçalvez, M.M. Máximo, J.C. Rosa-e-Silva, F.J. Candido-dos-Reis, A.A. Nogueira. Hormone therapy is not associated to pain thresholds in healthy postmenopausal women. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 66-71.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog4358.2019     OR     https://ceog.imrpress.com/EN/Y2019/V46/I1/66

[1] T.-H. Kim, E. S. Lee, H.-H. Lee, J.-M. Kim, Y.-S. Kim, B. Lee. Vaginal health: insights, views, and attitudes (VIVA). Results from a survey in South Korea[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 938-942.
[2] Y. Zheng, G. Niu, H. Zhang, W. Lu, Z. Liu. Estrogen replacement therapy is not a recommended therapy for postmenopausal women with coronary heart disease: a meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 219-226.
[3] L.E. Prado Correia, B.C. de Almeida, E. Chada Baracat, I. Silva, J.M. Soares Júnior, C.E. Bonduki, M. Abi Haidar. Efficacy and effects of transdermal hormone therapy in postmenopausal women[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 735-740.
[4] H. Zhou, W. Chen, X. Zhang, L. Wang. A case report of postmenopausal leiomyomatosis peritonealis disseminata[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 953-955.
[5] Q. Huang, S. Huang, J. Jiang, W.R. Cai, K.J. Yin, X.J. Chen. Clinical and radiographic characteristics in pulmonary endometriosis: based on five cases[J]. Clinical and Experimental Obstetrics & Gynecology, 2015, 42(3): 336-338.
[6] A. Traianos, D. Vavilis, A. Makedos, A. Karkanaki, K. Ravanos, N. Prapas, B.C. Tarlatzis. Effect of short-term tibolone treatment on risk markers for cardiovascular disease in healthy postmenopausal women: a randomized controlled study[J]. Clinical and Experimental Obstetrics & Gynecology, 2013, 40(4): 542-545.
[7] M.A. Osmanağaoğlu, S.C. Karahan, T. Aran, S. Güven, A. Cora, M. Kopuz, H. Bozkaya. The effects of hormone therapy on ischemia modified albumin and soluble CD40 ligand levels in obese surgical menopausal women[J]. Clinical and Experimental Obstetrics & Gynecology, 2013, 40(3): 389-392.
[8] P.F.R. Margarido, V.R. Bagnoli, Â. Maggio da Fonseca, G.A.R. Maciel, J.M. Soares Jr., É.A. D’Amico, E.C. Baracat. Transdermal estrogen therapy effects on fibrinogen levels in women with a past history of venous thromboembolism: a pilot study[J]. Clinical and Experimental Obstetrics & Gynecology, 2011, 38(3): 232-235.
[9] H. Hassa, H.M. Tanir, T. Oge. Is placebo as effective as estrogen regimens on vasomotor symptoms in women with surgical menopause?[J]. Clinical and Experimental Obstetrics & Gynecology, 2010, 37(2): 135-137.
[10] Ch. Akrivis, M. Varra, A. Thodos, G. Hadjopoulos, A. Bellou, N. Antoniou. Action of 25 µg 17 B-oestradiol vaginal tablets in the treatment of vaginal atrophy in Greek postmenopausal women; clinical study[J]. Clinical and Experimental Obstetrics & Gynecology, 2003, 30(4): 235-238.
[11] A. O. Mueck, H. Seeger, F. P. Armbruster, T. H. Lippert. The influence of norethisterone acetate on urinary urodilatin excretion in postrnenopausal women[J]. Clinical and Experimental Obstetrics & Gynecology, 1998, 25(3): 76-78.
[12] A. O. Mueck, H. Seeger, F. P. Armbruster, T. H. Lippert. Urinary excretion of insulin after estradiol treatment of postmenopausal women[J]. Clinical and Experimental Obstetrics & Gynecology, 1997, 24(1): 11-13.
[13] T. H. Lippert, F. P. Armbruster, H. Seeger, A. O. Mueck, M. Zwirner, W. Voelter. Urinary excretion of relaxin after estradiol treatment of postrnenopausal women[J]. Clinical and Experimental Obstetrics & Gynecology, 1996, 23(2): 65-69.
No Suggested Reading articles found!